-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, H+R25XTcBZb+nxXiu+RKDpH1m4UWN2EEoNMKBwNH1aM630v1qfblyo0s2f9bq1sJ cG33Av+Coq5Tag5qPhlw4A== 0001193125-04-019300.txt : 20040211 0001193125-04-019300.hdr.sgml : 20040211 20040211121501 ACCESSION NUMBER: 0001193125-04-019300 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20040211 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20040211 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SALIX PHARMACEUTICALS LTD CENTRAL INDEX KEY: 0001009356 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943267443 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23265 FILM NUMBER: 04584788 BUSINESS ADDRESS: STREET 1: 8540 COLONNADE CENTER DR STREET 2: SUITE 501 CITY: RALEIGH STATE: NC ZIP: 27615 BUSINESS PHONE: 9198621000 MAIL ADDRESS: STREET 1: 8540 COLONNADE CENTER DR STREET 2: SUITE 501 CITY: RALEIGH STATE: NC ZIP: 27615 FORMER COMPANY: FORMER CONFORMED NAME: SALIX HOLDINGS LTD DATE OF NAME CHANGE: 19970807 8-K 1 d8k.htm FORM 8-K FORM 8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported) February 11, 2004

 

 

SALIX PHARMACEUTICALS, LTD.

(Exact name of registrant as specified in its charter)

 

 

Delaware

(State or other jurisdiction of incorporation)

 

000-23265   94-3267443
(Commission file Number)   (IRS Employer ID Number)

 

8540 Colonnade Center Drive, Suite 501, Raleigh, North Carolina 27615

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code (919) 862-1000

 

Item 5. Other Events and Regulation FD Disclosure

 

On February 11, 2004, Salix Pharmaceuticals, Ltd. issued a press release announcing that the company will present at the Roth Capital Partners 16th Annual Growth Stock Conference in Dana Point, California on Wednesday, February 18 at 12:00 noon Eastern Time. A copy of this press release is attached.

 

Item 7. Financial Statements and Exhibits.

 

  (c) Exhibits

 

Exhibit No.
  

Description

99.1   Press release dated February 11, 2004.

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   

SALIX PHARMACEUTICALS, LTD.

Date: February 11, 2004

  

By:

  

/s/    Adam C. Derbyshire

       

Adam C. Derbyshire

       

Senior Vice President and

Chief Financial Officer

 EX-99.1 3 dex991.htm PRESS RELEASE PRESS RELEASE

Exhibit 99.1

 

FOR IMMEDIATE RELEASE

 

Contact:

   

Adam C. Derbyshire

     

Mike Freeman

    

Senior Vice President and

     

Director, Investor Relations and

    

Chief Financial Officer

     

Corporate Communications

    

919-862-1000

     

919-862-1000

 

SALIX PHARMACEUTICALS TO PRESENT AT ROTH

CAPITAL PARTNERS GROWTH STOCK CONFERENCE

 

RALEIGH, NC, February 11, 2004 - Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) today announced that the Company will present at the Roth Capital Partners 16th Annual Growth Stock Conference in Dana Point, CA on Wednesday, February 18 at 12:00 noon ET.

 

Interested parties can access a live audio web cast of the presentation at http://www.salix.com. A replay of the presentation will be available beginning at 3:00 p.m. ET, Wednesday, February 18 and will be available through Tuesday, February 24.

 

Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix’s strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company’s 100-member gastroenterology specialty sales and marketing team. Salix trades on the Nasdaq National Market under the ticker symbol “SLXP.”

 

For more information please contact the Company at 919-862-1000 or visit our web site at www.salix.com. Information on our web site is not incorporated in our SEC filings.

-----END PRIVACY-ENHANCED MESSAGE-----